Patents Assigned to Protein Design Labs, Inc.
-
Publication number: 20080175839Abstract: Described herein are methods and compositions that can be used for diagnosis and treatment of cancer.Type: ApplicationFiled: December 21, 2007Publication date: July 24, 2008Applicant: Protein Design Labs, Inc.Inventors: Debbie Law, Kurt C. Gish, Richard Murray, Patricia Culp
-
Publication number: 20080171039Abstract: Described herein are methods and compositions that can be used for diagnosis and treatment of cancer.Type: ApplicationFiled: December 21, 2007Publication date: July 17, 2008Applicant: Protein Design Labs, Inc.Inventors: Debbie Law, Kurt C. Gish, Richard Murray, Patricia Culp
-
Publication number: 20080025975Abstract: The invention provides bispecific antibodies with selective cytotoxicity against malignant B-cells. The bispecific antibodies bind to an effector cell antigen and to a 28/32 kDa heterodimeric protein on the surface of malignant B-cells. The invention also includes the monospecific components of the bispecific antibodies, humanized versions thereof, and humanized bispecific antibodies. The invention further provides therapeutic and diagnostic methods employing these antibodies.Type: ApplicationFiled: March 26, 2007Publication date: January 31, 2008Applicants: Protein Design Labs, Inc., Iowa Immunotherapy InvestigatorsInventors: George Weiner, Roger Gingrich, Brian Link, J. Tso
-
Patent number: 7022500Abstract: Novel methods for producing, and compositions of, humanized immunoglobulins having one or more complementarity determining regions (CDR's) and possible additional amino acids from a donor immunoglobulin and a framework region from an accepting human immunoglobulin are provided. Each humanized immunoglobulin chain will usually comprise, in addition to the CDR's, amino acids from the donor immunoglobulin framework that are, e.g., capable of interacting with the CDR's to effect binding affinity, such as one or more amino acids which are immediately adjacent to a CDR in the donor immunoglobulin or those within about about 3? as predicted by molecular modeling. The heavy and light chains may each be designed by using any one or all of various position criteria.Type: GrantFiled: November 22, 2000Date of Patent: April 4, 2006Assignee: Protein Design Labs, Inc.Inventors: Cary L. Queen, Harold E. Selick
-
Publication number: 20060024296Abstract: The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists.Type: ApplicationFiled: November 5, 2004Publication date: February 2, 2006Applicant: Protein Design Labs, Inc.Inventors: Marna Williams, J. Tso, Nicholas Landolfi, David Powers, Robert DuBridge, Debbie Law, Gao Liu
-
Publication number: 20060008415Abstract: The present invention is directed to stable protein derivatives, e.g., antibodies, antibody fragments or peptides, with at least one free thiol group coupled to N-acetyl-L-cysteine, N-ethyl-maleimide, or cysteine and the methods of making such derivatives. In addition, stable liquid pharmaceutical formulations comprising such proteins or their derivatives and stable lyophilized pharmaceutical formulations comprising such proteins are provided. The present invention is also directed to a method of making a stable Fab? fragment of an antibody and a method of controlling vascularization in injured or cancerous tissue comprising applying to the injured tissue one or more doses of the pharmaceutical formulations.Type: ApplicationFiled: June 24, 2005Publication date: January 12, 2006Applicant: Protein Design Labs, Inc.Inventors: Elisabet Kaisheva, Supriya Gupta, Weichang Zhou, Robert Weinkam, Patrick Powers, Naichi Liu, Vanitha Ramakrishnan
-
Patent number: 6933368Abstract: The present invention provides methods for producing mutationally-altered immunoglobulins and compositions containing such mutationally-altered immunoglobulins, wherein the mutationally-altered immunoglobulins have at least one mutation that alters the pattern of glycosylation in a variable region and thereby modifies the affinity of the immunoglobulin for a preselected antigen. The methods and compositions of the invention provide immunoglobulins that possess increased affinity for antigen. Such glycosylation-altered immunoglobulins are suitable for diagnostic and therapeutic applications.Type: GrantFiled: February 25, 2002Date of Patent: August 23, 2005Assignees: Protein Design Labs, Inc., Memorial Sloan Kettering Cancer CenterInventors: Man Sung Co, David A. Scheinberg, Cary L. Queen
-
Patent number: 6894149Abstract: This invention provides anti-HLA-DR antibodies and the methods of use thereof for the treatment of leukemia or lymphomas, or solid tumors such as ovarian cancer or melanoma.Type: GrantFiled: October 10, 2002Date of Patent: May 17, 2005Assignee: Protein Design Labs, Inc.Inventors: J. Yun Tso, Jennifer McPhate Green
-
Publication number: 20050019323Abstract: The present invention provides a method of treating autoimmune diseases. In particular, it provides a method for the treatment of Crohn's disease or psoriasis comprising administering to a subject in need thereof a therapeutically effective amount of an antibody against interferon ?.Type: ApplicationFiled: March 19, 2004Publication date: January 27, 2005Applicant: Protein Design Labs, Inc.Inventors: Rolf Ehrhardt, Daniel Levitt, Beth Layug, Don O'Neill, Nancy Wedel, Lars Ostberg
-
Publication number: 20040253606Abstract: Described herein are methods and compositions that can be used for diagnosis and treatment of soft tissue sarcoma cancer phenotypes and soft tissue sarcoma cancer-associated diseases. Also described herein are methods that can be used to identify modulators of soft tissue sarcoma cancer.Type: ApplicationFiled: November 26, 2003Publication date: December 16, 2004Applicant: Protein Design Labs, Inc.Inventors: Natasha Aziz, Wendy M. Ginsburg, Albert Zlotnik
-
Patent number: 6780586Abstract: Described herein are methods that can be used for diagnosis and prognosis of breast cancer. Also described herein are methods that can be used to screen candidate bioactive agents for the ability to modulate breast cancer. Additionally, methods and molecular targets (genes and their products) for therapeutic intervention in breast cancer are described.Type: GrantFiled: October 30, 2000Date of Patent: August 24, 2004Assignee: Protein Design Labs, Inc.Inventors: Kurt C. Gish, David Mack
-
Publication number: 20040141983Abstract: Described herein are methods and compositions that can be used for diagnosis and treatment of cancer.Type: ApplicationFiled: January 29, 2004Publication date: July 22, 2004Applicant: Protein Design Labs, Inc.Inventors: Debbie Law, Kurt C. Gish, Richard Murray, Patricia Culp
-
Patent number: 6762020Abstract: Described herein are methods that can be used for diagnosis and prognosis of breast cancer. Also described herein are methods that can be used to screen candidate bioactive agents for the ability to modulate breast cancer. Additionally, methods and molecular targets (genes and their products) for therapeutic intervention in breast cancer are described.Type: GrantFiled: August 18, 2000Date of Patent: July 13, 2004Assignee: Protein Design Labs, Inc.Inventors: David H. Mack, Kurt C. Gish
-
Publication number: 20040115814Abstract: The present invention provides methods for site-specific recombination in a cell, as well as vectors which can be employed in such methods. The methods and vectors of the present invention can be used to obtain persistent gene expression in a cell and to modulate gene expression. One preferred method according to the invention comprises contacting a cell with a vector comprising an origin of replication functional in mammalian cells located between first and second recombining sites located in parallel. Another preferred method comprises, in part, contacting a cell with a vector comprising first and second recombining sites in antiparallel orientations such that the vector is internalized by the cell. In both methods, the cell is further provided with a site-specific recombinase that effects recombination between the first and second recombining sites of the vector.Type: ApplicationFiled: September 30, 2003Publication date: June 17, 2004Applicant: Protein Design Labs, Inc.Inventor: Robert B. DuBridge
-
Patent number: 6750013Abstract: Described herein are methods that can be used for diagnosis and prognosis of breast cancer. Also described herein are methods that can be used to screen candidate bioactive agents for the ability to modulate breast cancer. Additionally, methods and molecular targets (genes and their products) for therapeutic intervention in breast cancer are described.Type: GrantFiled: December 21, 2000Date of Patent: June 15, 2004Assignee: Protein Design Labs, Inc.Inventors: Kurt C. Gish, David Mack
-
Publication number: 20040052783Abstract: The invention provides bispecific antibodies with selective cytotoxicity against malignant B-cells. The bispecific antibodies bind to an effector cell antigen and to a 28/32 kDa heterodimeric protein on the surface of malignant B-cells. The invention also includes the monospecific components of the bispecific antibodies, humanized versions thereof, and humanized bispecific antibodies. The invention further provides therapeutic and diagnostic methods employing these antibodies.Type: ApplicationFiled: May 9, 2003Publication date: March 18, 2004Applicants: Protein Design Labs, Inc., Iowa Immunotherapy InvestigatorsInventors: George Weiner, Roger Gingrich, Brian K. Link, J. Yun Tso
-
Publication number: 20040049014Abstract: Novel methods for producing, and compositions of, humanized immunoglobulins having one or more complementarity determining regions (CDR's) and possible additional amino acids from a donor immunoglobulin and a framework region from an accepting human immunoglobulin are provided. Each humanized immunoglobulin chain will usually comprise, in addition to the CDR's, amino acids from the donor immunoglobulin framework that are, e.g., capable of interacting with the CDR's to effect binding affinity, such as one or more amino acids which are immediately adjacent to a CDR in the donor immunoglobulin or those within about about 3 Å as predicted by molecular modeling. The heavy and light chains may each be designed by using any one or all of various position criteria.Type: ApplicationFiled: March 13, 2003Publication date: March 11, 2004Applicant: Protein Design Labs, Inc.Inventors: Cary L. Queen, Man Sung Co, William P. Schneider, Nicholas F. Landolfi, Kathleen L. Coelingh, Harold E. Selick
-
Patent number: 6682890Abstract: Described herein are methods that can be used for diagnosis and prognosis of colorectal cancer. Also described herein are methods that can be used to screen candidate bioactive agents for the ability to modulate colorectal cancer. Additionally, methods and molecular targets (genes and their products) for therapeutic intervention in colorectal cancer are described.Type: GrantFiled: May 8, 2001Date of Patent: January 27, 2004Assignee: Protein Design Labs, Inc.Inventors: David Mack, Kurt C. Gish, Keith E. Wilson
-
Publication number: 20030229208Abstract: Novel methods for producing, and compositions of, humanized immunoglobulins having one or more complementarity determining regions (CDR's) and possible additional amino acids from a donor immunoglobulin and a framework region from an accepting human immunoglobulin are provided. Each humanized immunoglobulin chain will usually comprise, in addition to the CDR's, amino acids from the donor immunoglobulin framework that are, e.g., capable of interacting with the CDR's to effect binding affinity, such as one or more amino acids which are immediately adjacent to a CDR in the donor immunoglobulin or those within about about 3 Å as predicted by molecular modeling. The heavy and light chains may each be designed by using any one or all of various position criteria.Type: ApplicationFiled: March 13, 2003Publication date: December 11, 2003Applicant: Protein Design Labs, Inc.Inventors: Cary L. Queen, Man Sung Co, William P. Schneider, Nicholas F. Landolfi, Kathleen L. Coelingh, Harold E. Selick
-
Publication number: 20030054497Abstract: The present invention provides methods for producing mutationally-altered immunoglobulins and compositions containing such mutationally-altered immunoglobulins, wherein the mutationally-altered immunoglobulins have at least one mutation that alters the pattern of glycosylation in a variable region and thereby modifies the affinity of the immunoglobulin for a preselected antigen. The methods and compositions of the invention provide immunoglobulins that possess increased affinity for antigen. Such glycosylation-altered immunoglobulins are suitable for diagnostic and therapeutic applications.Type: ApplicationFiled: February 25, 2002Publication date: March 20, 2003Applicant: PROTEIN DESIGN LABS, INC.Inventors: Man Sung Co, David A. Scheinberg, Cary L. Queen